唑来膦酸联合培美曲塞方案治疗非小细胞肺癌骨转移疗效研究.pdfVIP

1528 2010 11 15 11 陈石 李田 葛海波 ! (NSCLC) 60 NSCLC, , 30, 30 , , ( CR+ PR) 167% , ( CR+ PR + SD) 60. 0% ; ( CR+ PR ) 133% , ( CR+ PR+ SD) 533% 75 ( 2~ 17 ) , 7, 6 ( CR + PR ) 400% , ( CR + PR + NC) 833% , 133% , 367% (P 005) 792% , 458% (P 005) NSCLC, , ! ;; ; Study on Z oled ron ic ac id comb ined w ith p em etrexed in th e treatm en t of Advanced nonsm all cell lun g cancer w ith bon e m etastasis Chen Shi, L i Tian, G eH aiB o (NO 2 Pneum ology D ep artm ent, N anj ing ChestH osp ital, J iangsu Pro ince 210029, China ) A bstract! A im Obser ation the efficacy of zoledron ic acid com b inedw ith pem etrexed in treatm ent ofnonsm all cell lung cancer ( NSCLC) w ith bon e m etastasis. M ethods 60 cases of NSCLC patients w ith bone m etastases w ere random ly di ided into two group s, nam ely the zoledron ic acid group of 30 patients in control group 30 cases. Zoledronic acid group recei ed zoledron ic acid com b ined w ith pem etrexed chem otherapy, and the contro lgroup w as recei ed smi ply pem etrexed chem otherapy. R esults The control Efficient ofLung le sion s Zo ledron ic acid group: ( CR+ PR) 167% , ( CR+ PR+ SD ) 600% ; control group: ( CR + PR ) 133% , ( CR + PR + SD) 533% ; Th e o era ll a erage sur i al per iodw as 75m onths ( 2~ 17 m onths) , w ith a m edian sur i al tmi e zoledron ic acid group of 7 m onth s and 6 m onths in th e control group. Contro l of bone lesion s: Zoledron ic acid group: ( CR+ PR ) 400% , ( CR + PR+ SD ) 833% ; control group: ( CR+ PR ) 133% , ( CR + PR+ SD) 367% (P 005) . The rate of bone m etastasis pain relief zoledron ic acid group 792% , control group 458% (P 005) . Conclusion Zoledron ic acid com b ined w ith p emetrexed ch em otherapy forNSCLC w ith bonem etastasis ha e a good treatm